Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**triclosan + fluoride + Cavistat** is a combination oral care formulation intended for use in dentifrices (toothpastes) to prevent dental caries and promote overall oral health. \n- **Triclosan** is an antimicrobial agent that inhibits bacterial growth, particularly targeting the enoyl-acyl carrier protein reductase enzyme (ENR) in bacteria to suppress fatty acid synthesis, leading to cell death and reduced dental plaque and gingivitis[4][5]. \n- **Fluoride** is well-established for its role in remineralizing tooth enamel and preventing dental caries through inhibition of demineralization and enhancement of remineralization in tooth surfaces[6]. \n- **Cavistat** is less well-documented but is referenced in clinical trials as part of an anti-caries dentifrice formulation, possibly acting as a calcium phosphate delivery agent or remineralization component (such as a complex like arginine-based or CPP-ACP analog), though precise mechanism is not specified in available sources[2]. \nClinical studies show that combinations similar to triclosan + fluoride + copolymer formulations significantly reduce supragingival calculus formation and prevent caries and gingivitis when applied topically via toothpastes[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triclosan + fluoride + Cavistat.